Clinical Trial Update: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects [Phase 3]

View source ↗

Summary

Phase III study comparing Icaritin to Sorafenib in PD-L1 positive advanced hepatocellular carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Icaritin (icaritin)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Beijing Shenogen Biomedical Co., Ltd | Conditions: Hepatocellular Carcinoma (HCC) | Phase 3 | Status: TERMINATED